Share on StockTwits

Stock analysts at Morgan Stanley decreased their target price on shares of Chimerix (NASDAQ:CMRX) from $34.00 to $33.00 in a report issued on Monday. Morgan Stanley’s target price would suggest a potential upside of 37.90% from the stock’s previous close.

CMRX has been the subject of a number of other recent research reports. Analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Tuesday, July 8th. They set a “buy” rating and a $33.00 price target on the stock. Four analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $33.25.

Chimerix (NASDAQ:CMRX) opened at 23.93 on Monday. Chimerix has a 1-year low of $12.96 and a 1-year high of $27.69. The stock’s 50-day moving average is $22. and its 200-day moving average is $21.03. The company’s market cap is $853.6 million.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.05. Analysts expect that Chimerix will post $-1.64 EPS for the current fiscal year.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Receive News & Ratings for Chimerix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.